Singapore Blood-based Biomaker For Sports Medicine Market Size & Outlook
Singapore blood-based biomaker for sports medicine market, 2018-2030 (US$M)
Related Markets
Singapore blood-based biomaker for sports medicine market highlights
- The Singapore blood-based biomaker for sports medicine market generated a revenue of USD 3.3 million in 2023 and is expected to reach USD 5.7 million by 2030.
- The Singapore market is expected to grow at a CAGR of 8.1% from 2024 to 2030.
- In terms of segment, ck was the largest revenue generating type in 2023.
- CRP is the most lucrative type segment registering the fastest growth during the forecast period.
Blood-based biomaker for sports medicine market data book summary
| Market revenue in 2023 | USD 3.3 million |
| Market revenue in 2030 | USD 5.7 million |
| Growth rate | 8.1% (CAGR from 2023 to 2030) |
| Largest segment | Ck |
| Fastest growing segment | CRP |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | CK, Myoglobin, Lactate, WBC, Urea, CRP, Lipid and Protein Hydroperoxides, IL-6 |
Other key industry trends
- In terms of revenue, Singapore accounted for 0.5% of the global blood-based biomaker for sports medicine market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China blood-based biomaker for sports medicine market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 25.9 million by 2030.
Ck was the largest segment with a revenue share of 18.18% in 2023. Horizon Databook has segmented the Singapore blood-based biomaker for sports medicine market based on ck, myoglobin, lactate, wbc, urea, crp, lipid and protein hydroperoxides, il-6 covering the revenue growth of each sub-segment from 2018 to 2030.
In Singapore, the rise in sports injuries has prompted a significant increase in investments in sports medicine. With growing participation in various sports, injuries, such as strains, sprains, and fractures, have become more prevalent. More than 16,000 individuals experience sports-related injuries annually in Singapore.
The Singaporean government and private sector have substantially boosted funding for sports medicine research and infrastructure to address these challenges. This investment has spurred advancements in the field, particularly in the use of blood-based biomarkers for injury prevention and recovery. Blood-based biomarkers, such as Creatine Kinase (CK) and myoglobin, are increasingly utilized to monitor athletes’ health and performance, aiding in the early detection of potential injuries and optimizing recovery strategies.
These biomarkers are crucial for assessing muscle damage and inflammation, enhancing the overall effectiveness of injury management and rehabilitation programs in the sports sector.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Blood-based Biomaker for Sports Medicine Market Scope
Blood-based Biomaker for Sports Medicine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Singapore blood-based biomaker for sports medicine market size, by type, 2018-2030 (US$M)
Singapore Blood-based Biomaker for Sports Medicine Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
